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6/j.bWe describe a novel animal model of nonmyeloablative bone marrow transplantation (BMT) using the purine
analog pentostatin. Other cohorts of mice received another purine analog, fludarabine, which we and others
have previously evaluated in nonmyeloablativemurinemodels.We evaluated pentostatin for its ability to (1) op-
erate synergistically with cyclophosphamide to induce host T cell depletion; (2) induce host T cell suppression,
as defined bymodulation of cytokine secretion in vitro and abrogation of host-versus-graft reactivity in vivo; (3)
constrain host T cell recovery post-therapy; and (4) prevent the rejection of T cell–depleted, fully major histo-
compatibility complex–mismatched bone marrow allografts. Relative to single-agent regimens, combination
regimens with pentostatin and cyclophosphamide (PC) and with fludarabine and cyclophosphamide (FC)
worked synergistically to deplete host CD41 and CD81 T cells. PC and FC regimens were developed that
yielded similar levels of host T cell andmyeloid cell depletion. In the setting of these generally comparable states
of host T cell and myeloid cell depletion, the PC regimen was found to be highly immunosuppressive, as
evidenced by a reduced host T cell capacity to secrete interleukin-2 and interferon-g in vitro, to mediate
host-versus-graft reactivity in vivo, and to recover numerically and functionally during a 2-week observation
period after chemotherapy. Finally, using B6 hosts treated with the 14-day chemotherapy regimens, the PC
regimen more consistently prevented the rejection of BALB/c T cell–depleted allografts compared with the
FC regimen (rate of alloengraftment, 14/15 [93%] of PC-treated recipients vs 8/14 [57%] of FC-treated
recipients; P\ .05); similar results were observed using an 8-day conditioning regimen. These data suggest
that host T cell suppression, distinct from T cell depletion, may be a critical determinant of engraftment after
purine analog–based regimens and also may be preferentially attained by the use of pentostatin.
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Reduced-intensity conditioning regimens before al-
logeneic bone marrow transplantation (BMT) avoid the
severe bone marrow (BM) toxicity associated with mye-
loablative regimens, but increase the barrier of host
immunity to donor engraftment [1,2]. Fludarabine,
which has been used to inhibit host immunity before
transplantation, belongs to a class of purine nucleoside
analogs that mediate cytotoxicity by incorporation
into DNA and blockade of elongation by DNA
polymerase [3]. Initial nonmyeloablative regimens used
fludarabine in combination with idarubicin or total
body irradiation (TBI) [4,5], and current regimens also
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cyclophosphamide [6,7]. Other purine analogs, such as
pentostatin, have been less frequently evaluated for host
preparation before transplantation.
Pentostatin is a purine analog with a unique mecha-
nism of action relative to fludarabine. It inhibits adeno-
sine deaminase, thereby resulting in lymphocyte toxicity
due to the accumulationofdeoxyadenosine triphosphate
[8,9]. Indeed, an inherited deficiency of adenosine
deaminase is one cause of congenital severe combined
immunodeficiency, a disease in which both B cells and
T cells fail to mature [10]. In the setting of hairy cell
leukemia [11] or graft-versus-host disease therapy [12],
pentostatin results in profound reduction in host immu-
nity, which has been characterized primarily in numeri-
cal terms, specifically as a reduction of absolute T cell
counts. Despite the compelling potential of pentostatin
formodulating host immunity, only a limited number of
clinical trials have evaluated this drug for nonmyeloabla-
tive transplantation [13,14]. Furthermore, to the best of
our knowledge, no direct comparative data exist
regarding the relative immune modulation effects of
fludarabine and pentostatin in the clinic or in animal
models. As such, whether distinct purine analogs
might result in differential efficacy in host preparation
for alloengraftment is unclear.
In previous work, we found that fludarabine and
cyclophosphamide acted synergistically to induce
a depth of immune depletion sufficient to facilitate
major histocompatibility complex (MHC)-mismatched,
T cell–depleted murine alloengraftment [15]. The
fludarabine-based model that we used was stringent in
terms of studying host-versus-graft rejection (HVGR)
given the major MHC mismatch and the use of T cell–
depleted allografts. Because no reports exist in the liter-
ature pertaining to the ability of pentostatin to facilitate
alloengraftment after experimentalmurineBMT,we set
out to develop murine models focusing on host condi-
tioning with pentostatin. Based on our previous finding
that fludarabine and cyclophosphamide acted in syn-
ergy, we evaluated pentostatin both alone and in combi-
nation with this DNA alkylator. Although host natural
killer cells can mediate rejection [16], we focused our
studies on purine analog modulation of host CD41
and CD81 T cells, which are key mediators of graft re-
jection [17] and known targets of purine analog therapy.
The present study had 3 specific objectives. First, we
characterized the ability of pentostatin to cause immune
depletion when used in combination with cyclophos-
phamide and characterized the immune recovery after
such depletion. Second, we examined the immunosup-
pressive effect of pentostatin-containing regimens; that
is, we tested whether T cells that survived host condi-
tioning could mediate effector function, including gen-
eration of an in vivo HVGR response on adoptive cell
transfer to a secondary host. Finally, we evaluated the
ability of pentostatin-containing regimens to facilitatestable, long-term engraftment of MHC-mismatched,
T cell–depleted BM allografts.MATERIALS AND METHODS
Mice
Adult female C57BL/6 (B6, H-2Kb) and BALB/c
(H-2Kd) mice, age 8-10 weeks, were obtained from
the Frederick Cancer Research Facility. The mice
were maintained in a specific pathogen-free facility
and treated in accordance with an approved animal
protocol. Drinking water was supplemented with
ciprofloxacin from day -7 before to day114 after che-
motherapy (concentration, 100 mg/L; water intake
volume not monitored).
Preparative Regimen
The B6 and BALB/cmice were treated by i.p. injec-
tion with either pentostatin (Ben Venue Labs; Bedford,
OH) or fludarabine (Teva Parenteral Medicines; Irvine,
CA), administered either alone or in combination with
cyclophosphamide (Bristol-Myers Squibb; Princeton,
NJ). Control cohorts received cyclophosphamide alone,
vehicle (Hank’s balanced salt solution [HBSS]), or lethal
TBI (BALB/c, 950 cGy; B6, 1100 cGy; 137Cs gamma ra-
diation).Thedrug schedules varied for each experiment.
BMT
BM cells were harvested and T cell–depleted (anti-
CD90 [Thy1.2]MicroBeads; Miltenyi Biotec, Auburn,
CA). The BM product contained\1% CD31 cells as
determined by flow cytometry. Host T cells for post-
irradiation add-back were obtained from the spleen
and were purified to .99% purity (Pan T Cell Isola-
tion Kit; Miltenyi Biotec). After the preparative regi-
men was completed, the T cell–depleted BM was
injected i.v. into hosts at a dose of 2  107 cells per
recipient.
Determination of Cytokine Phenotype
Recipient spleen cells were harvested, and red cells
were lysed (ACK Buffer; Quality Biological; Gaithers-
burg, MD) and adjusted to 0.5  106 cells/mL in 24-
well plates. Anti-CD3– and anti-CD28–coated beads
(CD3/CD28 beads) were produced as described previ-
ously [18]. Spleen T cells were costimulated (bead:
Tcell ratio of 3:1) for 24hours incompletemediumcon-
sisting of RPMI 1640 (Mediatech; Manassas, VA), 10%
fetal calf serum (Gemini Bio-Products, Invitrogen;
Carlsbad, CA), penicillin-streptomycin-glutamine,
nonessential amino acids (Invitrogen, Carlsbad, CA),
and 2-ME (5  1025 M; Invitrogen). In some experi-
ments, T cells were stimulated with B6 or BALB/c
dendritic cells (DCs) (spleen cell:DC ratio of 10:1)
for 24 hours. The resulting culture supernatants were
622 Biol Blood Marrow Transplant 17:620-631, 2011J. Mariotti et al.evaluated for cytokine content by a multiplex bead
array (Bio-Plex Assay; Bio-Rad; Hercules, CA).
Secondary Transfer Experiments
BALB/c mice were treated for 3 days with pentos-
tatin plus cyclophosphamide (PC) or with fludarabine
plus cyclophosphamide (FC); control hosts received
TBI. Spleen cells were harvested on the day after
the end of treatment, and T cells were purified. These
T cells were then injected i.v. into BALB/c hosts that
had been lethally irradiated 24 hours before injection.
On the day after host T cell infusion, mice were
challenged with fully allogeneic T cell–depleted BM
(B6 donors; 10  106 cells injected i.v.). HVGR was
quantified on day 5 after BM infusion.Quantification of HVGR
Post-BMT, splenic single cells were adjusted to
0.5  106 cells/mL and stimulated with B6 or BALB/
c DCs. These DCs were generated by culturing BM
cells for 6 days in recombinant mouse granulocyte-
macrophage colony stimulating factor and recombi-
nant mouse interleukin (IL)-4 (each at 1000 IU/mL;
PeproTech; Rocky Hill, NJ), with bacterial lipopoly-
saccharide (1 mg/mL; Calbiochem; San Diego, CA)
added for the final 24 hours of DC culture. Expanded
DCs were washed and used at a spleen cell:DC ratio of
10:1. After 24 hours, supernatants were collected for
cytokine analysis, and cells were evaluated by cytokine
capture flow cytometry using interferon (IFN)-g catch
reagent (Miltenyi Biotec), followed by 45 minutes of
incubation (in RPMI 1640 with 10% fetal calf serum)
at 37C (slow rotation). Cells were washed with cold
buffer, labeled with IFN-g detection antibody and
previously described surface antibodies, washed, and
analyzed. Flow cytometry frequency data were multi-
plied by splenic cell yields to obtain the absolute num-
ber of cytokine-secreting cells per spleen; allospecific
values were calculated by subtracting values obtained
after syngeneic stimulation.Determination of Chimerism
Spleens and BM were harvested at different times
after the end of treatment, and single-cell suspensions
were labeled with anti-CD3, -CD4, -CD8, -NK1.1, or
-Gr1 and conjugated with fluorescein isothiocyanate,
phycoerythrin, or IFN-g detection antibody (Phar-
Mingen; Franklin Lakes, NJ). For chimerism analysis,
post-BMT blood, spleen, and BM cells were labeled
with anti–H-2Kb and anti–H-2Kd to differentiate do-
nor versus host, and with anti-B220 or anti-CD19,
-CD3, and -Gr1 to identify cell lineage. Four-color
flow cytometry was performed on a FACSCalibur
instrument (BD; Franklin Lakes, NJ); 5-color flow
cytometry was performed on an LSR II instrumentusing FACSDiva software (BD). Between 10,000 and
20,000 live events were acquired, with 7-aminoactino-
mycin D used to exclude dead cells. The percentage of
donor chimerism was calculated using the following
equation:
% donor chimerism ðdonor cells=½host cells
1 donor cellsÞ  100:
Statistical Analysis
Survival analyses were performed according to the
Kaplan-Meier method, and survival curves were com-
pared using log-rank tests. Flow and cytokine data
were analyzed using the Student two-tailed t test.
P values\.05 were considered statistically significant.RESULTS
Pentostatin Combined with Cyclophosphamide
Synergistically Induces Host Immune Depletion
and Immunosuppression
To evaluate the immune depletion and immunosup-
pression caused by pentostatin and fludarabine, we chose
a dose of fludarabine (100 mg/kg/day) known to be
effective in treating leukemia and associated with
a defined incidence of neurotoxicity [19]; of note, this
was the same dose of fludarabine that we previously eval-
uated in combination with cyclophosphamide [15]. In
comparison, pentostatin exerts immunosuppressive ac-
tivity at a dose of1mg/kg/day [20],with increasing tox-
icity at doses of.1mg/kg/day [21].On the basis of these
data, we initiated our experiments using pentostatin at
a dose of 1 mg/kg/day. In previous work [15], we found
that fludarabine caused minimal immune-depleting
effects unless combinedwith cyclophosphamide; this ob-
servation is consistent with the characterized synergistic
relationship between purine analogs and alkylating
agents [22]. Therefore, in our initial experiments, which
were designed to detect synergy between the different
purine analogs and theDNA alkylator, we used an inter-
mediatedoseof cyclophosphamide thatwehad studied in
previous work [15].
We first evaluated a 3-day regimen of pentostatin or
fludarabine both alone and in combination with cyclo-
phosphamide. Either purine analog alone had aminimal
effect on host myeloid cell depletion; however, the addi-
tion of cyclophosphamide significantly and similarly re-
duced host myeloid cells to a level that did not approach
that seenwithmyeloablativeTBI (Figure 1A, left panel).
Because these PC and FC regimens yielded similar my-
eloid cell depletion, we were able to assess whether they
mediated different immunosuppressive and immunode-
pletive effects when controlled for myeloid cell toxicity.
Recipients of either pentostatin or fludarabine alone had
Figure 1. Pentostatin and cyclophosphamide synergistically induce host immune depletion and suppression. BALB/c hosts were injected i.p. once daily
for 3 days with HBSS (vehicle), pentostatin (P; 1 mg/kg/day), fludarabine (F; 100 mg/kg/day), cyclophosphamide (C50; 50 mg/kg/day), pentostatin plus
cyclophosphamide (P/C50), or rfludarabine plus cyclophosphamide (F/C50), or treated with lethal TBI (XRT; 950 cGy). (A), At 3 days post-therapy,
spleen cells were isolated, counted, and analyzed by flow cytometry to determine the levels of depletion of myeloid cells (Gr-11) and CD41 and
CD81 T cells. (B), Spleen cells were costimulated, and the resultant 24-hour supernatant was tested for IFN-g and IL-2 content. (C), In a separate ex-
periment, BALB/c hosts were lethally irradiated and then injected with syngeneic BALB/c host T cells (0.1 106 cells) obtained from mice treated with
HBSS (control), lethal irradiation (XRT; 1050 cGy), pentostatin plus cyclophosphamide (P/C50), or fludarabine plus cyclophosphamide (F/C50). One day
after injection of host T cells, the hosts underwent transplantation with fully MHC-mismatched T cell–depleted BM fromB6mice (10 106 cells). On day
8 post-BMT, spleen cells were isolated and stimulated with syngeneic or allogeneic DCs for 24 hours. The number of host CD41 and CD81 cells pro-
ducing allospecific IFN-gwas determined by cytokine capture flow cytometry. (D), Resultant culture supernatants were also tested for cytokine content;
the allogeneic stimulation condition is shown. All results are reported as mean 6 SEM of n 5 5-10 per cohort.
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reduction, 25% and 17%, respectively); CD41 T cells
decreased by 48% in recipients of single-agent therapy
with cyclophosphamide (Figure 1A, middle panel). Incontrast, recipients of the PC or FC regimen had
marked CD41 T cell depletion, to levels below what
would be expected if the purine analog and alkylator
hadanadditive effect (PC:92%CD41depletion [actual]
624 Biol Blood Marrow Transplant 17:620-631, 2011J. Mariotti et al.vs 74% depletion [calculated value if additive], P\ .05;
FC: 84% CD41 depletion [actual] vs 66% depletion
[calculated value if additive], P\ .05). In this experi-
ment, the PC regimen caused slightly more severe
CD41 T cell depletion than the FC regimen and had
comparable depletion to that froma lethalTBI regimen.
Similar synergy between the purine analog and DNA
alkylator was seen in terms of CD81 T cell depletion
(PC: 90% CD81 depletion [actual] vs 64% depletion
[calculated value if additive], P\ .05; FC: 85% CD81
depletion [actual] vs. 57% depletion [calculated value
if additive], P\ .05) (Figure 1A, right panel). The PC
and FC regimens demonstrated comparably severe
CD81 T cell depletion, and both regimens caused less
depletion than the TBI regimen.
We next evaluated pentostatin- and fludarabine-
containing regimens for their immunosuppressive ef-
fect, as defined by a reduced capacity of post-therapy
host splenocytes to secrete cytokines. Post-therapy
splenocytes were normalized to equal cell concentra-
tions, and the cytokine secretion potential was tested.
As anticipated, post-TBI splenocytes were immuno-
suppressed relative to control splenocytes in terms of
IFN-g secretion (median value, 13 pg/mL vs. 2 pg/
mL; P\ .01) and IL-2 secretion (median value, 134
pg/mL vs 8 pg/mL; P\ .001) (Figure 1B). In marked
contrast, post-therapy splenocytes from single-agent
pentostatin, fludarabine, or cyclophosphamide recipi-
ents demonstrated unexpected increases in IFN-g
and IL-2 secretion. Such ‘‘rebound’’ cytokine produc-
tion was ameliorated by the PC regimen and, to a lesser
extent, by the FC regimen.
We also evaluated whether T cells harvested from
PC-and FC-treated hosts were immunosuppressed, as
demonstrated by a reduced capacity to mount an in
vivo alloreactive HVGR. Host-type T cells harvested
from FC-treated mice induced a similar magnitude
of HVGR as control host T cells, as defined by allospe-
cific IFN-g–secreting CD41 and CD81 T cells
(Figure 1C). In contrast, host-type T cells harvested
from PC- or lethal TBI-treated mice mediated greatly
reduced CD41- and CD81-driven HVGR. HVGR
was also greatly reduced in recipients of PC-treated
host T cells when evaluated by IFN-g and IL-2 super-
natant analysis (Figure 1D).Host Immune Recovery after PC or FCTherapy:
A Potential Barrier to Engraftment
We next tested the combination PC and FC regi-
mens in a fullyMHC-mismatchedBMTsetting.Despite
the significant host immunosuppression and immune
depletion caused by these regimens, graft rejection was
uniformly observed (Figure 2A). Of note, PC-treated
hosts had reduced CD41- and CD81-mediated HVGR
compared with FC-treated hosts; however, recipients ofeither regimen had increasedHVGR relative to TBI re-
cipients (Figure 2B).
Given the occurrence ofHVGR and graft rejection
in PC- and FC-treated hosts, we reasoned that the im-
munosuppressive and immunodepletive states induced
by these 3-day regimens might have been too transient
to allow for clinically meaningful engraftment. As
such, we set out to characterize the periods of immu-
nosuppression and immune depletion and to develop
alternative regimens with enhanced durability. The
absolute numbers of CD41 and CD81 T cells in-
creased progressively between day 3 and day 10 after
either the PC or FC regimen (Figure 2C). Strikingly,
splenocytes harvested from mice at days 6 and 10
after the PC regimen exhibited a markedly increased
capacity for IFN-g secretion relative to splenocytes
harvested immediately after completion of the PC
regimen (Figure 2D). In comparison, FC-treated
spleen cells secreted moderately increased amounts
of IFN-g immediately post-therapy, with sustained el-
evation seen throughout the 10-day period.Intensified PC and FC Regimens: Profound
Immune Depletion
Our data indicate that more severe host T cell
depletion and impaired immune recovery might be re-
quired to permit fully MHC-mismatched engraftment
after PC or FC therapy. Thus, we sought to develop
regimens that would yield both CD41 and CD81
T cell depletion to levels comparable to that achieved
by lethal doses of TBI. For this purpose, we tested
regimens that incorporated either pentostatin or
fludarabine every third day in combination with daily
cyclophosphamide for 14 days. This intermittent
purine analog therapy, which was necessitated by the
increased toxicity from prolonged daily administra-
tion, theoretically takes advantage of the relatively
long biological half-life of purine analogs [3]. Similar
to the results with the 3-day regimen, splenic CD41
T cells in both the 14-day PC and FC combinations
were greatly reduced compared with the numbers
seen in single-drug regimens (Figure 3A, left panel).
Consistent with our objective, recipients of the 14-
day PC or FC regimen demonstrated more profound
CD41Tcell depletion in the spleen compared with re-
cipients of the lethal TBI regimen. Similar intensive
immune depletion was observed on evaluation of BM
after PC and FC treatments; that is, the numbers of
CD41 T cells harvested from PC or FC recipients
were reduced to levels equivalent to those seen in lethal
TBI-treated hosts (Figure 3A, right panel). Host mice
that received combination therapy were also more se-
verely depleted of splenic CD81T cells than recipients
of a single-drug regimen (Figure 3B, left panel),
with levels comparable to those seen after lethal
TBI. PC and FC regimens, as well as single-agent
Figure 2. Host immune recovery after PC or FC therapy. (A), BALB/c hosts underwent transplantation with T cell–depleted B6 BM cells (10  106
cells) after conditioning with either lethal irradiation (XRT; 1050 cGy), pentostatin plus cyclophosphamide (P/C), or fludarabine plus cyclophosphamide
(F/C). A graft rejection control group received lethal TBI, followed by an infusion of unmanipulated host T cells (0.1 106). Spleen cells were isolated on
day 8 post-BMTand analyzed by flow cytometry for percent age donor cells. (B), In addition, the total number of day 8 post-BMT host CD41 andCD81 T
cells producing IFN-g after 24 hours of stimulation with syngeneic (BALB/c) or allogeneic (B6) DCs was determined. The results shown are with allo-
geneic stimulation. (C), In a separate experiment, BALB/c mice were injected i.p. once daily for 3 days with HBSS, pentostatin plus cyclophosphamide (P/
C50), or fludarabine plus cyclophosphamide (F/C50) or treated with lethal TBI (XRT). Subsequently, spleen cells were obtained at days 3, 6, and 10 after
therapy and analyzed by flow cytometry for number of CD41 and CD81 T cells. (D), In addition, spleen cells at each time point were costimulated, and
the resultant supernatants were tested for IFN-g content. All results are reported as mean 6 SEM of n 5 5 per cohort for each time point.
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Figure 3. Intensified PC and FC regimens result in profound immune depletion. (A), Host B6 mice were treated with a 14-day course of either pen-
tostatin (P; 1 mg/kg on days 1, 4, 8, and 12) or fludarabine (F; 100 mg/kg on days 1, 4, 8, and 12) alone, daily cyclophosphamide alone (C100; 100 mg/kg/
day), a combination of intermittent pentostatin or fludarabine with daily cyclophosphamide (P/C100 or F/C100), or lethal TBI (1150 cGy). Spleen cells
were isolated and evaluated by flow cytometry for total number of CD41 and CD81 T cells and myeloid (Gr-11) cells. (B), BM cells were also analyzed
for T cell composition and myeloid lineage. All results are reported as mean 6 SEM of n 5 5 per cohort.
626 Biol Blood Marrow Transplant 17:620-631, 2011J. Mariotti et al.cyclophosphamide alone, mediated profound deple-
tion of CD81 T cells in the BM to values below those
obtained with the TBI regimen (Figure 3B, right
panel). Natural killer cells were equally depleted by
the PC regimen and the FC regimen (data not shown).
In addition to the induction of profound immune
depletion, the 14-day PC or FC regimen also mediated
substantial depletion of myeloid cells. Recipients of
the PC regimen demonstrated a similar reduction in
the number of splenic Gr-11 cells as TBI recipients
(Figure 3C, left panel); recipients of the FC regimen
also had greatly reduced splenic Gr-11 cells, although
not to the levels seen in the lethal TBI recipients.
Myeloid cells in the BM were preserved in PC and
FC recipients, who had approximately 2-log greater
numbers of myeloid cells in the BM compared with
lethal TBI recipients (Figure 3C, right panel).
Thus, both the 14-day PC and FC regimens were
nonmyeloablative yet yielded similar depletion ofhost CD41 and CD81 T cells compared with lethal
TBI.Intensified PC and FC Regimens: Kinetics
of Immune Recovery
We next evaluated whether the 14-day PC and FC
regimens might limit the immune T cell recovery that
wasobservedwith the3-day regimens. In this experiment,
splenic CD41Tcell depletionwasmore profound in FC
recipients compared with the PC recipients (Figure 4A
and B, ‘‘day 0’’ values); however, at days 7 and 14 post-
therapy, substantial recovery of splenic CD41 T cells
was seen in FC recipients but not in PC recipients
(Figure 4A, left panel). Indeed, the number of splenic
CD41 T cells at days 7 and 14 post-therapy was greater
in FC recipients than in PC recipients. In addition,
splenic CD81 T cells, which were depleted to similar
levels immediately after PC and FC chemotherapy,
Figure 4. An intensified PC regimen effectively constrains host immune recovery. (A), Host B6mice received either pentostatin (1 mg/kg on days 1, 4, 8
and 12) or fludarabine (100 mg/kg on days 1, 4, 8, and 12), each in combination with cyclophosphamide (100 mg/kg/day on days 1-14). After treatment,
spleen cells were harvested on days 0, 7, and 14 post-therapy and evaluated by flow cytometry for total number of CD41 and CD81 T cells and myeloid
(Gr-11) cells. (B), BM cells were also harvested on days 0, 7, and 14 post-therapy and analyzed for T cell composition and myeloid lineage. (C), On days 0,
7, and 14 post-therapy, spleen cells were stimulated with anti-CD3/CD28 beads, and the 24-hour supernatant was tested for IFN-g and IL-2 content. All
results are reported as mean 6 SEM of n 5 5 per cohort for each time point.
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recipients at day 7 post-therapy (Figure 4A, middle
panel). An approximate 2-log increase in splenic Gr-11
myeloid cells was seen in both PC and FC recipients in
the 2-week post-therapy period.
Compared with the PC regimen, the FC regimen
induced more profound CD41 T cell depletion in the
BM(Figure 4B, left panel).This enhancedCD41deple-
tion was relatively transient, because levels of marrow
CD41T cells were actually higher in FC recipients rel-
ative to PC recipients at day 14 post-therapy. Similarly,
FC recipients had more profound CD81 T cell deple-
tion in the marrow immediately post-treatment, but
had increased CD81 T cell numbers at day 7 post-
therapy (Figure 4B, middle panel). In contrast to this
severe host T cell depletion, myeloid cells in the BM
were relatively spared in both regimens, with furtherGr-11 myeloid cell recovery occurring over 14 days
(Figure 4B, right panel). Recovery of myeloid cells was
somewhat constrained in PC recipients relative to FC
recipients at days 7 and 14 post-therapy. Taken
together, these data suggest that PC recipients had less
capacity for T cell recovery post-therapy compared
with FC recipients; that is, FC recipients in general
had lower CD41 and CD81 T cell numbers in the
spleen andmarrow immediately post-therapy, but expe-
riencedmore rapid recoveryofCD81Tcell numbers by
day 7 post-therapy and higher CD41T cell numbers at
day 14 post-therapy.
Given this evidence of constrained immune T cell
recovery after the 14-day regimens, particularly the
PC regimen, we investigated whether the functional
T cell rebound observed with the 3-day regimensmight
be similarly constrained. Indeed, splenocytes from PC
Figure 5. Alloengraftment after intensified PC and FCregimens (14-day regimen). (A), Host B6mice received treatmentwith the 14-day PCor FC regimen
and subsequently underwent transplantationwith T cell–depleted BALB/c BM (20 106 cells). The percentage of total donor cells in the bloodwas evaluated
by flow cytometry at 30, 60, and 90 days post-BMT. (B), The percentage of donor cells in the spleen and BM was determined on day 90 post-BMT.
628 Biol Blood Marrow Transplant 17:620-631, 2011J. Mariotti et al.recipients had minimal capacity to secrete IFN-g and
IL-2; remarkably, this T cell dysfunction persisted
over the 2-week post-therapy period (Figure 4C). Com-
pared with PC recipients, FC recipients had a modestly
increased splenocyte capacity for IFN-g and increased
recovery of IFN-g and IL-2 secretion at day 14 post-
therapy.Table 1. Pentostatin Facilitates Fully MHC-Disparate Mini-
Transplantation
Cohort Engraftment* Statistics
TBI 5/5
Cyclophosphamide 0/10
PC 14/15 PC > FC, P < .05
FC 8/14
Peripheral blood was analyzed on day 30 post-BMT.
*Chimerism values >1% donor.Intensified PC and FC Regimens: Successful
Abrogation of Graft Rejection
Having shown the ability of the intensified PC and
FC regimens to induce profound host immune deple-
tion and immunosuppression with limited immune re-
covery, we hypothesized that such regimens would
prevent graft rejection in a fullyMHC-disparate trans-
plantation model. Indeed, 14/15 recipients of PC con-
ditioning and 8/14 recipients of FC conditioning
demonstrated alloengraftment on peripheral blood
analysis at day 30 post-BMT (Table 1; PC . FC,
P\ .05). In contrast, recipients of single-agent cyclo-
phosphamide conditioning did not engraft (0/10 cases
of alloengraftment). For both PC and FC recipients,
alloengraftment was relatively stable at days 60 and
90 post-BMT (Figure 5A). Of note, the PC regimen
yielded several cases of stable mixed chimerism,
whereas engraftment in FC recipients was generally
an all-or-none phenomenon. Three recipients of the
PC regimen died between day 30 and day 90 post-
BMT; no overt clinical signs of graft-versus-host
disease (eg, skin lesions, diarrhea) were noted in these
patients. At day 90 post-BMT, chimerism analysis ofharvested spleen and BM confirmed the peripheral
blood results, with an increased frequency of successful
alloengraftment in PC recipients compared with FC
recipients (Figure 5B) (cases of alloengraftment, day
90 spleen analysis: 10/12 in PC recipients vs. 8/14 in
FC recipients, P\ .05; cases of alloengraftment, day
90 BM analysis: 12/12 in PC recipients vs. 9/14 in
FC recipients, P\ .05).
The PC and FC regimens that we evaluated yielded
similar levels of host immune T cell depletion, and as
such, the differing alloengraftment results observed
might have been due to some other effect of the condi-
tioning, such as differences in immunosuppression or in
the capacity for immune recovery. Alternatively, it is
possible that higher doses of fludarabinemight have im-
proved alloengraftment in the FC recipients. As a step
toward addressing this latter possibility, we performed
a second BMT experiment using 8-day PC (with the
same pentostatin dose, 1 mg/kg, used in previous exper-
iments) and FC (with the fludarabine dose increased
from 100 mg/kg to 200 mg/kg) conditioning regimens.
In this experiment, we found that the PC and FC
Figure 6. Alloengraftment after intensified PC and FC regimens (8-day regimen; increased fludarabine dose). Host B6 mice received either pentostatin
(1 mg/kg on days 1, 4, and 7) or fludarabine (200 mg/kg on days 1, 4, and 7). Each drug was administered in combination with cyclophosphamide (100 mg/
kg/day on days 1-8; F200C and PC regimens). After treatment, cohorts of mice were euthanized (n 5 10 in each cohort), spleens and marrow were
harvested, and the absolute numbers of postconditioning CD31 T cells, CD41 T cells, CD81 T cells, B cells, and Gr-11 myeloid cells were quantified
by flow cytometry. ‘‘Host’’ indicates cell subset numbers in untreated host mice. Absolute cell numbers (mean 6 SEM) in the spleen are shown in (A),
whereas absolute cell numbers in the marrow are shown in (B). NS, not statistically significant. Other cohorts of mice treated with the F200C regimen
(n5 10) and the PC regimen (n5 5) underwent subsequent transplantation with T cell–depleted BALB/c BM (20 106 cells). The percentage of donor/
host chimerism was then determined by flow cytometry on day 28 post-BMT for total cells, CD31 T cells, CD41 T cells, CD81 T cells, B2201 B cells,
and Gr-11 cells in the spleen (C) and the BM (D). ‘‘Host’’ and ‘‘donor’’ values represent chimerism control values obtained from untreated host and
donor mice, respectively. Results are reported as mean 6 SEM.
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ble extent and caused a similar marked depletion of
total CD31 T cells, CD41 T cells, CD81 T cells,
and B cells (P 5 not significant for each comparison)(Figure 6). Moreover, similar to the previous BMT ex-
periment, recipients of the PC regimen had increased
alloengraftment compared with recipients of the FC
regimen (Figure 6).
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In the present study, we characterized the immuno-
depletive and immunosuppressive properties of pentos-
tatin combined with cyclophosphamide and identified
novel pentostatin-based regimens that facilitate the
engraftment of fully MHC-disparate, T cell–depleted
murine BM allografts. We found that both pentostatin
and fludarabine profoundly influenced host immunity,
but we also identified potentially important differences
in effects. Pentostatin and fludarabine were relatively
comparable in their ability to operate synergistically
with a secondary agent, the DNA alkylator cyclophos-
phamide, to achieve marked immune T cell depletion.
However, in experimental settings that yielded compa-
rable host T cell depletion, we consistently observed
that the PC regimen mediated more severe immune
function deficits relative to the FC regimen. Indeed,
recipients of the PC regimen were less likely to reject
a T cell–depleted, fully MHC-disparate BM allograft
than were recipients of the FC regimen.
Our finding that pentostatin worked synergistically
with cyclophosphamide to achieve severe hostT cell de-
pletion extends our previous findings with respect to
fludarabine and cyclophosphamide [15], providing fur-
ther in vivo evidence to support the previously de-
scribed synergy between purine analogs and DNA
alkylators [23,24]. This synergy results from purine
analog–induced inhibition of DNA synthesis and
repair, thereby enhancing T cell susceptibility to
DNA-damaging agents [3]. The PC and FC regimens
that we evaluated not only were similar in terms of
host CD41 and CD81 T cell depletion, but also were
nonmyeloablative and generally equivalent in terms of
the extent of myeloid cell depletion achieved. The sim-
ilar immuneT cell andmyeloid cell depletion profiles of
these regimens gave us the opportunity to compare
pentostatin- and fludarabine-based regimens for their
ability tomediate immunosuppression, as defined by re-
duced T cell effector function in vitro and a decreased
capacity to mediate HVGR in vivo. Although we evalu-
ated PC and FC regimens that were similarly immuno-
depletive across all of the experiments performed, it is
possible that the different immunosuppression, im-
mune recovery, and alloengraftment results seen with
the PC and FC regimens would have been minimized
had higher doses of fludarabine been used. However,
in an experiment performed as a step toward evaluating
this possibility, we found that host conditioning with an
FC regimen containing a 100% higher dose of fludara-
bine (increased from 100 mg/kg to 200 mg/kg) yielded
a lower rate of alloengraftment than the PC regimen. A
further fludarabine dosage increase in our model likely
would not be feasible, given the reported LD10 of a sin-
gle dose of fludarabine of 234 mg/kg [25]. It is also im-
portant to note that significant species effects exist with
respect to nucleoside analog metabolism [26], and assuch, it is difficult to predict the degree to which the
current experimental findings would translate to the
clinic.
Our present experimental results support the con-
cept that chemotherapy-mediated host immune T cell
suppression represents an important and separate pa-
rameter from immune T cell depletion. In comparison,
our previous murine experiments that evaluated fludar-
abine and cyclophosphamide conditioning focused
solely on immune cell depletion as a biomarker for the
host’s capacity tomediate graft rejection [15].The initial
experiments in the present study, which used 3-day
treatment regimens, yielded two findings supporting
our conclusion that pentostatin mediated a more pro-
found host T cell suppression compared with fludara-
bine. First, we found that T cells remaining after
purine analog therapy alone paradoxically had an in-
creased capacity for cytokine secretion. We speculate
that this ‘‘rebound’’ of functionmight be related to a rel-
ative resistance of cytokine-secreting effector T cells to
purine analog therapy. Importantly, adding cyclophos-
phamide to the pentostatin therapy, but not to the flu-
darabine therapy, minimized this post-therapy increase
in host T cell cytokine secretion. Second, in adoptive
transfer experiments, we found that T cells harvested
from recipients of the PC regimen had a reduced capac-
ity to mediate HVGR relative to T cells harvested from
recipients of the FC regimen.
Furthermore, experiments that evaluated post-
therapy immuneT cell recovery also point to the prefer-
ential immunosuppressive effects of pentostatin. After
both the 3-day and intensified 14-day treatment regi-
mens, the PC recipients demonstrated less recovery of
Tcell numbers and lowerTcell cytokine secretion com-
pared with the FC recipients. Remarkably, recipients of
the 14-day PC regimen, but not those of the 14-day FC
regimen, exhibited minimal evidence of numerical or
functional T cell recovery over a 2-week observation pe-
riod. Further studies are needed to examine whether
these different effectsmight be the result of pentostatin’s
inhibition of adenosine deaminase and the resultant
accumulation of adenosine, which potently inhibits
T cell function [27,28]. Of note, T cells of Th1/Tc1
phenotype, which are known to mediate murine
marrow graft rejection [29], are preferentially sensitive
to the immunosuppressive effects of adenosine [30]. It
is possible that this differential immune recovery capac-
ity might have accounted for, at least in part, the more
consistent ability of the PC regimen to prevent fully
MHC-disparate marrow graft rejection compared with
the FC regimen.
In summary, we found that pentostatin combined
with cyclophosphamide caused severe host immune
T cell depletion in a nonmyeloablative manner and in-
duced profound immunosuppression in residual host
T cells. Specifically, pentostatin effectively impaired
host T cell recovery in both numerical and functional
Biol Blood Marrow Transplant 17:620-631, 2011 631Pentostatin-Induced Host T Cell Functional Deficitsterms, with resultant abrogation of alloantigen-driven
rejection responses. These data add to the limited
body of knowledge regarding the immunosuppressive
effects of purine analogs and may facilitate further
murine research pertaining to nonmyeloablative trans-
plantation. Finally, these results help provide a rationale
for future pilot clinical trials of nonmyeloablative
transplantation using pentostatin in combination with
cyclophosphamide.ACKNOWLEDGMENTS
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